HJLI Hancock Jaffe Laboratories, Inc.

Hancock Jaffe Laboratories, Inc.

Medical/Dental Instruments

Health Care

Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.

IPO Year: 2018

Exchange: NASDAQ

Website: hancockjaffe.com

Peers

$NVNO

Recent Analyst Ratings for Hancock Jaffe Laboratories, Inc.

Date	Price Target	Rating	Analyst

See more ratings

Hancock Jaffe Laboratories, Inc.

Peers

Recent Analyst Ratings for Hancock Jaffe Laboratories, Inc.

Hancock Jaffe Laboratories, Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Gray Robert converted options into 1,042 units of Common Stock, increasing direct ownership by 19% to 6,614 units

SEC Form 4: Jenusaitis Matthew converted options into 1,042 units of Common Stock, increasing direct ownership by 22% to 5,884 units

SEC Form 4: Jenusaitis Matthew bought $10,010 worth of Common Stock (1,300 units at $7.70), increasing direct ownership by 37% to 4,842 units

SEC Form 4: Gray Robert bought $12,500 worth of Common Stock (2,000 units at $6.25), increasing direct ownership by 56% to 5,572 units

SEC Form 4: Glickman Marc H. bought $9,440 worth of Common Stock (1,600 units at $5.90)

SEC Form 4: BERMAN ROBERT ANDREW bought $16,410 worth of Common Stock (3,000 units at $5.47), increasing direct ownership by 408% to 3,736 units

SEC Form 4: Duhay Francis bought $50,592 worth of Common Stock (9,492 units at $5.33), increasing direct ownership by 259% to 13,160 units

SEC Form 4 filed by Craig Glynn

SEC Form 3 filed by Craig Glynn

SEC Form 4 filed by Francis Duhay